RU2010152693A - Способы, композиции и приборы для облегчения регенерации - Google Patents
Способы, композиции и приборы для облегчения регенерации Download PDFInfo
- Publication number
- RU2010152693A RU2010152693A RU2010152693/10A RU2010152693A RU2010152693A RU 2010152693 A RU2010152693 A RU 2010152693A RU 2010152693/10 A RU2010152693/10 A RU 2010152693/10A RU 2010152693 A RU2010152693 A RU 2010152693A RU 2010152693 A RU2010152693 A RU 2010152693A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- functioning
- stage
- composition
- degree
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 24
- 239000000203 mixture Substances 0.000 title claims abstract 9
- 230000008929 regeneration Effects 0.000 title claims abstract 3
- 238000011069 regeneration method Methods 0.000 title claims abstract 3
- 210000004027 cell Anatomy 0.000 claims abstract 17
- 230000022534 cell killing Effects 0.000 claims abstract 7
- 230000002062 proliferating effect Effects 0.000 claims abstract 5
- 239000003053 toxin Substances 0.000 claims abstract 4
- 238000002604 ultrasonography Methods 0.000 claims abstract 4
- 230000013595 glycosylation Effects 0.000 claims abstract 3
- 238000006206 glycosylation reaction Methods 0.000 claims abstract 3
- 230000028709 inflammatory response Effects 0.000 claims abstract 3
- 230000008439 repair process Effects 0.000 claims abstract 3
- 230000030833 cell death Effects 0.000 claims abstract 2
- 210000000170 cell membrane Anatomy 0.000 claims abstract 2
- 230000006378 damage Effects 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 230000005865 ionizing radiation Effects 0.000 claims abstract 2
- 238000012544 monitoring process Methods 0.000 claims abstract 2
- 210000000822 natural killer cell Anatomy 0.000 claims abstract 2
- 230000010355 oscillation Effects 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 231100000765 toxin Toxicity 0.000 claims abstract 2
- 108700012359 toxins Proteins 0.000 claims abstract 2
- 239000012636 effector Substances 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Electromagnetism (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
Abstract
1. Способ обеспечения процессов регенерации у пациента, включающий стадии: ! (а) выбора методики для дифференциального уничтожения клеток обратно пропорционально степени функционирования клеток и прямо пропорционально предпочтительному эффекту на непролиферирующие клетки у пациента; и ! (b) применения указанной методики для увеличения доли клеток, обладающих степенью функциональности. ! 2. Способ по п.1, где указанное дифференциальное уничтожение клеток включает применение ультразвука к клеткам. ! 3. Способ по п.1, где указанная стадия выбора включает стадию выбора уровня дозировки антител к конечным продуктам гликозилирования. ! 4. Способ по п.1, где способ дополнительно включает стадию контроля за воспалительными ответами. ! 5. Способ по п.1, где указанная стадия выбора включает стадию выбора из группы, состоящей по существу из ультразвука и других осцилляционных методов для разрушения мембран клеток или структур, приводя к клеточной смерти, EMF, света высокой интенсивности, радиоволновых микроволн, лазеров, магнитных явлений и ионизирующего излучения, химических токсинов, антител против частично функционирующих или полностью нефункционирующих клеток, конъюгатов антител-токсинов и клеток натуральных киллеров, модифицированных для экспрессии целеспецифических антител. ! 6. Композиция для применения в способе, обеспечивающем регенеративные процессы, где указанная композиция отличается дифференциальным уничтожением клеток на основании обратного взаимоотношения со степенью функционирования клеток при защите функционирующих пролиферирующих клеток. ! 7. Композиция по п.6, где указанная композиция включает
Claims (9)
1. Способ обеспечения процессов регенерации у пациента, включающий стадии:
(а) выбора методики для дифференциального уничтожения клеток обратно пропорционально степени функционирования клеток и прямо пропорционально предпочтительному эффекту на непролиферирующие клетки у пациента; и
(b) применения указанной методики для увеличения доли клеток, обладающих степенью функциональности.
2. Способ по п.1, где указанное дифференциальное уничтожение клеток включает применение ультразвука к клеткам.
3. Способ по п.1, где указанная стадия выбора включает стадию выбора уровня дозировки антител к конечным продуктам гликозилирования.
4. Способ по п.1, где способ дополнительно включает стадию контроля за воспалительными ответами.
5. Способ по п.1, где указанная стадия выбора включает стадию выбора из группы, состоящей по существу из ультразвука и других осцилляционных методов для разрушения мембран клеток или структур, приводя к клеточной смерти, EMF, света высокой интенсивности, радиоволновых микроволн, лазеров, магнитных явлений и ионизирующего излучения, химических токсинов, антител против частично функционирующих или полностью нефункционирующих клеток, конъюгатов антител-токсинов и клеток натуральных киллеров, модифицированных для экспрессии целеспецифических антител.
6. Композиция для применения в способе, обеспечивающем регенеративные процессы, где указанная композиция отличается дифференциальным уничтожением клеток на основании обратного взаимоотношения со степенью функционирования клеток при защите функционирующих пролиферирующих клеток.
7. Композиция по п.6, где указанная композиция включает антитела к конечным продуктам гликозилирования.
8. Прибор для применения в способе, обеспечивающем регенеративные процессы, указанный прибор характеризуется дифференциальным уничтожением клеток на основании степени функциональности клеток при защите функционирующих пролиферирующих клеток.
9. Прибор по п.8, где указанный прибор включает эффектор, который разрушает клетки, монитор, который определяет воспалительный ответ, и контрольное устройство, которое определяет уровень действия эффектора.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5584608P | 2008-05-23 | 2008-05-23 | |
US61/055,846 | 2008-05-23 | ||
PCT/US2009/044951 WO2009143411A2 (en) | 2008-05-23 | 2009-05-22 | Methods, compositions and apparatus for facilitating regeneration |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015114990A Division RU2640249C2 (ru) | 2008-05-23 | 2009-05-22 | Способы, композиции и приборы для облегчения регенерации |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010152693A true RU2010152693A (ru) | 2012-06-27 |
RU2553225C2 RU2553225C2 (ru) | 2015-06-10 |
Family
ID=41340916
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015114990A RU2640249C2 (ru) | 2008-05-23 | 2009-05-22 | Способы, композиции и приборы для облегчения регенерации |
RU2010152693/10A RU2553225C2 (ru) | 2008-05-23 | 2009-05-22 | Способ облегчения регенерации |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015114990A RU2640249C2 (ru) | 2008-05-23 | 2009-05-22 | Способы, композиции и приборы для облегчения регенерации |
Country Status (19)
Country | Link |
---|---|
US (4) | US20110105961A1 (ru) |
EP (3) | EP2789684B1 (ru) |
JP (6) | JP2011521009A (ru) |
KR (4) | KR20120127543A (ru) |
CN (2) | CN104987416A (ru) |
AU (1) | AU2009248945B2 (ru) |
BR (1) | BRPI0913047A2 (ru) |
CA (1) | CA2724886C (ru) |
DK (1) | DK2789684T3 (ru) |
ES (2) | ES2499395T3 (ru) |
HK (2) | HK1150628A1 (ru) |
HU (1) | HUE031902T2 (ru) |
IL (3) | IL209513A (ru) |
MX (2) | MX342994B (ru) |
PL (1) | PL2789684T3 (ru) |
PT (1) | PT2789684T (ru) |
RU (2) | RU2640249C2 (ru) |
WO (1) | WO2009143411A2 (ru) |
ZA (1) | ZA201008209B (ru) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10226531B2 (en) | 2010-09-27 | 2019-03-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120127543A (ko) * | 2008-05-23 | 2012-11-21 | 시와 코퍼레이션 | 재생을 촉진하는 방법, 조성물 및 장치 |
WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
RU2014128010A (ru) | 2011-12-13 | 2016-02-10 | Бак Инститьют Фо Рисерч Он Эйджин | Способы улучшения средств консервативной терапии |
WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
WO2014089124A1 (en) | 2012-12-03 | 2014-06-12 | Cenexys, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
CN105518149A (zh) | 2013-03-24 | 2016-04-20 | 奥依信生物技术公司 | 靶细胞内治疗性蛋白的靶向产生的系统和方法 |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
BR112017005517A2 (pt) | 2014-09-19 | 2017-12-05 | Siwa Corp | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes |
KR20180056689A (ko) | 2015-10-13 | 2018-05-29 | 시와 코퍼레이션 | 항-age 항체 및 이의 사용 방법 |
EP3677598B1 (en) | 2016-02-19 | 2022-04-06 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
CN109311975A (zh) * | 2016-04-15 | 2019-02-05 | Siwa有限公司 | 用于治疗神经退行性紊乱的抗age抗体 |
JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US11525146B2 (en) | 2017-01-09 | 2022-12-13 | Oisin Biotechnologies, Inc. | Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof |
EP3619540A1 (en) | 2017-05-04 | 2020-03-11 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
WO2019204666A1 (en) | 2018-04-18 | 2019-10-24 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell |
JP2021532114A (ja) * | 2018-07-23 | 2021-11-25 | シワ コーポレーション | 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物 |
JP2021534144A (ja) * | 2018-08-23 | 2021-12-09 | シワ コーポレーション | Age修飾細胞を除去するための、抗カルボキシメチルリシン抗体及び超音波 |
KR20210101481A (ko) * | 2020-02-10 | 2021-08-19 | 한국과학기술연구원 | 초음파 출력부를 포함하는 노화세포 제거 장치 |
WO2021222758A1 (en) | 2020-05-01 | 2021-11-04 | Siwa Corporation | Methods of treating infections |
WO2022093195A1 (en) | 2020-10-27 | 2022-05-05 | Siwa Corporation | Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens |
US20240000930A1 (en) | 2020-12-09 | 2024-01-04 | Siwa Corporation | Methods and compositions for treating kidney diseases |
KR102650316B1 (ko) * | 2021-06-18 | 2024-03-25 | 재단법인대구경북과학기술원 | 초음파 자극이 가능한 자성 패치 및 그 제작 방법 |
CA3229602A1 (en) | 2021-08-20 | 2023-02-23 | Siwa Corporation | Methods and compositions for treating fibrotic diseases |
WO2024102157A1 (en) | 2022-11-09 | 2024-05-16 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Family Cites Families (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US5811075A (en) | 1984-03-19 | 1998-09-22 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
US4900747A (en) * | 1984-03-19 | 1990-02-13 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
AU600306B2 (en) * | 1986-09-12 | 1990-08-09 | Rockefeller University, The | Methods and agents for removing advanced glycosylation endproducts |
US4917951A (en) * | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4965288A (en) * | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20080063603A1 (en) * | 1990-04-02 | 2008-03-13 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
IN172208B (ru) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
US20040208826A1 (en) * | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6372249B1 (en) * | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
US5624804A (en) | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
EP0617599B1 (fr) * | 1991-12-20 | 1996-10-16 | Technomed Medical Systems | Appareil de therapie par ultrasons emettant des ondes ultrasoniques produisant des effets thermiques et des effets de cavitation |
WO1994000592A1 (en) * | 1992-06-26 | 1994-01-06 | Exocell, Inc. | Monoclonal antibodies against glycated low density lipoprotein |
US5620479A (en) * | 1992-11-13 | 1997-04-15 | The Regents Of The University Of California | Method and apparatus for thermal therapy of tumors |
US5518720A (en) * | 1992-12-30 | 1996-05-21 | Exocell, Inc. | Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin |
US6387373B1 (en) * | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
WO1994025616A1 (en) * | 1993-04-28 | 1994-11-10 | Worcester Foundation For Experimental Biology | Cell-targeted lytic pore-forming agents |
US5935927A (en) | 1994-02-03 | 1999-08-10 | The Picower Institute For Medical Research | Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts |
US6410598B1 (en) | 1994-02-03 | 2002-06-25 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
ATE245169T1 (de) * | 1994-12-30 | 2003-08-15 | Alteon Inc | Monoklonale antikörper spezifisch für endprodukte der fortgeschrittenen glycosylation in biologischen proben |
US5744318A (en) * | 1994-12-30 | 1998-04-28 | Alteon Inc. | Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples |
US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
WO1997007803A1 (en) | 1995-08-25 | 1997-03-06 | Case Western Reserve University | Process for detecting pentosidine and for assessing the biological age of a biological sample |
JP3579549B2 (ja) | 1995-10-24 | 2004-10-20 | 株式会社トクヤマ | 糖尿病または糖尿病合併症用マーカーとしての使用 |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US5664570A (en) | 1996-02-20 | 1997-09-09 | Svc | Apparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body |
US5908925A (en) * | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
US5984882A (en) * | 1996-08-19 | 1999-11-16 | Angiosonics Inc. | Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy |
US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US6245318B1 (en) * | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
AU8693598A (en) | 1997-08-08 | 1999-03-01 | University Of Washington | Isolation of a novel senescence-factor gene, p23 |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
US6896659B2 (en) * | 1998-02-06 | 2005-05-24 | Point Biomedical Corporation | Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
JP4016304B2 (ja) | 1998-02-26 | 2007-12-05 | 日本油脂株式会社 | モノクローナル抗体、ハイブリッド細胞、およびモノクローナル抗体の製造方法 |
WO1999064463A1 (en) * | 1998-06-09 | 1999-12-16 | Alteon Inc. | Monoclonal antibodies specific for guanidino group-derived advanced glycosylation endproducts in biological samples |
US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
JP2002526117A (ja) * | 1998-10-06 | 2002-08-20 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 細胞外新規rage結合タンパク質(en−rage)及びその使用 |
US6309355B1 (en) * | 1998-12-22 | 2001-10-30 | The Regents Of The University Of Michigan | Method and assembly for performing ultrasound surgery using cavitation |
ATE488250T1 (de) | 1999-03-02 | 2010-12-15 | Centocor Inc | Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma |
US6067859A (en) * | 1999-03-04 | 2000-05-30 | The Board Of Regents, The University Of Texas System | Optical stretcher |
DE10084743T1 (de) | 1999-06-25 | 2002-08-14 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern |
WO2001012598A2 (en) * | 1999-08-13 | 2001-02-22 | The Trustees Of Columbia University In The City Of New York | METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
WO2001018060A1 (fr) | 1999-09-08 | 2001-03-15 | Toray Industries, Inc. | Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique |
US6853864B2 (en) * | 2000-02-02 | 2005-02-08 | Catholic University Of America, The | Use of electromagnetic fields in cancer and other therapies |
EP1283728A2 (en) * | 2000-05-23 | 2003-02-19 | Amersham Health AS | Contrast agents |
NO312338B1 (no) * | 2000-08-25 | 2002-04-29 | Gunnar Myhr | Anordning for selektiv celle- eller virusödeleggelse hos en levende organisme |
CN2445326Y (zh) * | 2000-10-09 | 2001-08-29 | 刘永详 | 测定被糖化蛋白的免疫分析装置 |
US6676963B1 (en) * | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
US6821274B2 (en) * | 2001-03-07 | 2004-11-23 | Gendel Ltd. | Ultrasound therapy for selective cell ablation |
US7481781B2 (en) * | 2000-11-17 | 2009-01-27 | Gendel Limited | Ultrasound therapy |
US7347855B2 (en) | 2001-10-29 | 2008-03-25 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
CN100370961C (zh) | 2001-01-03 | 2008-02-27 | 超形态公司 | 溶解脂肪组织的装置 |
DE60202008T2 (de) * | 2001-03-22 | 2005-12-01 | Roche Diagnostics Gmbh | Verfahren zum Auffinden von Reagenzien und Festphasenkomponenten in spezifischen Bindungsassays, frei von fortgeschrittenen Glykosylierungsendprodukten |
EP1415997A4 (en) | 2001-07-19 | 2005-03-30 | Mitsubishi Pharma Corp | POLYPEPTIDES RELATING TO TRANSFER OF RECEPTOR SIGNALS FROM ADVANCED GLYCATION TERMINAL PRODUCTS |
JP4012722B2 (ja) | 2001-11-22 | 2007-11-21 | 株式会社トランスジェニック | カルボキシメチル化ペプチドに対する抗体 |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2004011460A2 (en) | 2002-07-24 | 2004-02-05 | Qlt, Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
CN1774445A (zh) | 2002-08-16 | 2006-05-17 | 惠氏公司 | 用于治疗rage相关病症的组合物和方法 |
US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
EP1601969A2 (en) * | 2003-03-08 | 2005-12-07 | Auvation Ltd | Markers for colorectal cancer |
US20060122543A1 (en) * | 2003-07-31 | 2006-06-08 | Woodwelding Ag | Method for promoting tissue regeneration on wound surfaces as device and treatment instrument or implant for carrying out method |
US7358226B2 (en) * | 2003-08-27 | 2008-04-15 | The Regents Of The University Of California | Ultrasonic concentration of drug delivery capsules |
EP2213310A1 (en) * | 2004-01-20 | 2010-08-04 | Sunnybrook and Women's College Health Sciences Centre | High frequency ultrasound imaging using contrast agents |
KR20070004730A (ko) * | 2004-02-17 | 2007-01-09 | 다이나미스 테라퓨틱스, 인코포레이티드 | 프룩토스아민 3 키나아제 및 콜라겐 및 엘라스틴의 형성 |
WO2006012415A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Rage protein derivatives |
AP2007003869A0 (en) | 2004-08-03 | 2007-02-28 | Transtech Pharma Inc | Rage fusion proteins and methods of use |
GB0422525D0 (en) | 2004-10-11 | 2004-11-10 | Luebcke Peter | Dermatological compositions and methods |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
EP1866663A1 (en) * | 2005-03-03 | 2007-12-19 | Bracco Research S.A. | Medical imaging system based on a targeted contrast agent |
JP2006249015A (ja) * | 2005-03-11 | 2006-09-21 | Mochida Pharmaceut Co Ltd | 細胞老化抑制剤 |
WO2006109599A1 (ja) | 2005-04-05 | 2006-10-19 | Jms Co., Ltd. | 3,4-DGEに由来するAGEsに特異的に反応する抗体 |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
WO2007027584A2 (en) * | 2005-08-30 | 2007-03-08 | University Of Virginia Patent Foundation | Deposit contrast agents and related methods thereof |
US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
US20070083120A1 (en) * | 2005-09-22 | 2007-04-12 | Cain Charles A | Pulsed cavitational ultrasound therapy |
US20070078290A1 (en) * | 2005-09-30 | 2007-04-05 | Esenaliev Rinat O | Ultrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues |
US7766833B2 (en) * | 2005-11-23 | 2010-08-03 | General Electric Company | Ablation array having independently activated ablation elements |
JP4779115B2 (ja) | 2005-12-16 | 2011-09-28 | 国立大学法人東北大学 | 早期肺癌の術後予後検査方法 |
US20100226932A1 (en) * | 2006-02-22 | 2010-09-09 | Novavax, Inc. | Adjuvant and Vaccine Compositions |
LT2676967T (lt) | 2006-02-28 | 2019-09-10 | Biogen Ma Inc. | Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu |
US9056905B2 (en) | 2007-05-21 | 2015-06-16 | Alderbio Holdings Llc | Antibodies to TNF-α and use thereof |
WO2008154638A2 (en) | 2007-06-12 | 2008-12-18 | Board Of Regents, The University Of Texas System | Antagonists of the receptor for advanced glycation end-products (rage) |
AU2008265983B2 (en) | 2007-06-14 | 2013-06-20 | Galactica Pharmaceuticals, Inc. | RAGE fusion proteins |
JP2007277263A (ja) | 2007-07-13 | 2007-10-25 | Transgenic Inc | カルボキシメチル化タンパク質に対する抗体 |
WO2009085216A2 (en) * | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
US7751057B2 (en) * | 2008-01-18 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Magnetomotive optical coherence tomography |
DE102008009461A1 (de) | 2008-02-15 | 2009-08-20 | Beiersdorf Ag | Verfahren zur Reduzierung der Zeichen der Hautalterung |
WO2009136382A2 (en) * | 2008-05-09 | 2009-11-12 | Abbott Gmbh & Co. Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
KR20120127543A (ko) | 2008-05-23 | 2012-11-21 | 시와 코퍼레이션 | 재생을 촉진하는 방법, 조성물 및 장치 |
JP5229473B2 (ja) * | 2008-06-04 | 2013-07-03 | 財団法人ヒューマンサイエンス振興財団 | 超音波医療装置 |
US20110319499A1 (en) | 2008-06-30 | 2011-12-29 | The Johns Hopkins University | Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease |
WO2010095461A1 (ja) | 2009-02-20 | 2010-08-26 | 国立大学法人東京大学 | 新規モノクローナル抗体、並びにその使用 |
WO2011035104A1 (en) * | 2009-09-17 | 2011-03-24 | Sanuwave, Inc. | Methods and devices for cleaning and sterilization with shock waves |
US20110070227A1 (en) | 2009-09-18 | 2011-03-24 | Anna-Marie Novotney-Barry | Treatment of Autoimmune and Inflammatory Diseases |
WO2011053322A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
WO2011101039A1 (en) | 2010-02-22 | 2011-08-25 | Universite Pierre Et Marie Curie (Paris 6) | Apparatus for the treatment of brain affections and method implementing thereof |
KR101351181B1 (ko) | 2010-05-11 | 2014-01-14 | 가천대학교 산학협력단 | 단핵식세포계 세포 내에서 age-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법 |
WO2012047629A2 (en) | 2010-09-27 | 2012-04-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of ather0sclerosis |
US8721571B2 (en) * | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
WO2012135616A1 (en) | 2011-03-31 | 2012-10-04 | Siwa Corporation | Vaccination against advanced glycation end-products |
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
KR102068728B1 (ko) | 2011-07-10 | 2020-01-21 | 가이디드 테라피 시스템스, 엘.엘.씨. | 초음파 치료를 위한 방법 및 시스템 |
US8954155B2 (en) | 2011-09-19 | 2015-02-10 | Biotalk Technologies Inc | Apparatus and method for rejuvenating skin |
AU2012311428A1 (en) | 2011-09-23 | 2014-04-24 | Julius-Maximilians-Universitat Wurzburg | Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
KR101939401B1 (ko) | 2011-11-10 | 2019-01-16 | 가천대학교 산학협력단 | 단핵식세포계 세포의 age-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물 |
JP6273214B2 (ja) | 2012-02-17 | 2018-01-31 | シアトル ジェネティックス, インコーポレイテッド | がんを処置するためのインテグリンαvβ6に対する抗体およびその使用 |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
US20130288980A1 (en) | 2012-04-02 | 2013-10-31 | Buck Institute For Research On Aging | Targeting senescent and cancer cells for selective killing by interference with foxo4 |
US10379026B2 (en) | 2012-08-29 | 2019-08-13 | Inguran, Llc | Cell processing using magnetic particles |
KR101520336B1 (ko) | 2012-11-30 | 2015-05-14 | 전남대학교산학협력단 | 패혈증 비브리오균의 편모 구성성분인 플라젤린과 병원체의 항원 단백을 융합시킨 재조합 단백을 포함하는 노화 예방, 개선 또는 치료용 조성물 |
EP2742935A1 (en) | 2012-12-14 | 2014-06-18 | Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH | SERF2 for the treatment of atrophy and for increasing cell growth |
JP6454650B2 (ja) | 2013-03-06 | 2019-01-23 | プロタリクス リミテッド | TNFαポリペプチド阻害剤を発現する植物細胞及び薬学的に許容される担体を含む医薬組成物 |
US20140257262A1 (en) | 2013-03-11 | 2014-09-11 | Alexandre Carpentier | Interstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same |
MX2015012808A (es) | 2013-03-12 | 2016-05-31 | Molecular Templates Inc | Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas. |
BR112016013861A2 (pt) | 2013-12-16 | 2017-10-10 | Genentech Inc | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
WO2015108998A2 (en) | 2014-01-15 | 2015-07-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Cartilage targeting agents and their use |
US10099027B2 (en) | 2014-01-24 | 2018-10-16 | Cole Research & Design | Oral suction device |
US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
DE102014107077B3 (de) | 2014-05-20 | 2015-08-13 | Ecs Engineered Control Systems Ag | Schaltvorrichtung |
US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
BR112017005517A2 (pt) | 2014-09-19 | 2017-12-05 | Siwa Corp | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes |
EP3207062A1 (en) | 2014-10-16 | 2017-08-23 | The Broad Institute Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
KR20180056689A (ko) | 2015-10-13 | 2018-05-29 | 시와 코퍼레이션 | 항-age 항체 및 이의 사용 방법 |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
KR102503910B1 (ko) | 2015-11-09 | 2023-02-27 | 삼성전자주식회사 | 기립 보조 방법 및 장치 |
EP3677598B1 (en) | 2016-02-19 | 2022-04-06 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
US10981021B2 (en) | 2016-03-11 | 2021-04-20 | Carthera | Method for transiently disrupting a region of the blood-brain barrier of a human |
CN109311975A (zh) | 2016-04-15 | 2019-02-05 | Siwa有限公司 | 用于治疗神经退行性紊乱的抗age抗体 |
JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10858449B1 (en) * | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
EP3619540A1 (en) | 2017-05-04 | 2020-03-11 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
JP2021532114A (ja) | 2018-07-23 | 2021-11-25 | シワ コーポレーション | 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物 |
CN112888788A (zh) | 2018-08-14 | 2021-06-01 | 艾梅尔生物治疗公司 | 用于治疗线粒体疾病或病症和异质性的方法和组合物 |
JP2021534144A (ja) | 2018-08-23 | 2021-12-09 | シワ コーポレーション | Age修飾細胞を除去するための、抗カルボキシメチルリシン抗体及び超音波 |
WO2021222758A1 (en) | 2020-05-01 | 2021-11-04 | Siwa Corporation | Methods of treating infections |
WO2021247397A2 (en) | 2020-06-04 | 2021-12-09 | Siwa Corporation | Methods and compositions for enhancing the immune system |
-
2009
- 2009-05-22 KR KR1020127026483A patent/KR20120127543A/ko active Application Filing
- 2009-05-22 BR BRPI0913047-0A patent/BRPI0913047A2/pt not_active Application Discontinuation
- 2009-05-22 ES ES09751639.7T patent/ES2499395T3/es active Active
- 2009-05-22 KR KR1020107026063A patent/KR20110000585A/ko not_active Application Discontinuation
- 2009-05-22 HU HUE14170802A patent/HUE031902T2/en unknown
- 2009-05-22 MX MX2014006768A patent/MX342994B/es unknown
- 2009-05-22 RU RU2015114990A patent/RU2640249C2/ru active
- 2009-05-22 PT PT141708024T patent/PT2789684T/pt unknown
- 2009-05-22 WO PCT/US2009/044951 patent/WO2009143411A2/en active Application Filing
- 2009-05-22 EP EP14170802.4A patent/EP2789684B1/en active Active
- 2009-05-22 EP EP09751639.7A patent/EP2294178B1/en active Active
- 2009-05-22 CA CA2724886A patent/CA2724886C/en active Active
- 2009-05-22 ES ES14170802.4T patent/ES2616728T3/es active Active
- 2009-05-22 KR KR1020137028228A patent/KR101537460B1/ko active IP Right Grant
- 2009-05-22 US US12/994,421 patent/US20110105961A1/en not_active Abandoned
- 2009-05-22 DK DK14170802.4T patent/DK2789684T3/en active
- 2009-05-22 JP JP2011511734A patent/JP2011521009A/ja active Pending
- 2009-05-22 CN CN201510303227.8A patent/CN104987416A/zh active Pending
- 2009-05-22 RU RU2010152693/10A patent/RU2553225C2/ru active
- 2009-05-22 AU AU2009248945A patent/AU2009248945B2/en active Active
- 2009-05-22 MX MX2010012473A patent/MX2010012473A/es active IP Right Grant
- 2009-05-22 CN CN200980118817.6A patent/CN102037119B/zh active Active
- 2009-05-22 EP EP16198527.0A patent/EP3170888A1/en not_active Withdrawn
- 2009-05-22 PL PL14170802T patent/PL2789684T3/pl unknown
- 2009-05-22 KR KR1020157007520A patent/KR101592156B1/ko active IP Right Grant
-
2010
- 2010-11-16 ZA ZA2010/08209A patent/ZA201008209B/en unknown
- 2010-11-23 IL IL209513A patent/IL209513A/en active IP Right Grant
-
2011
- 2011-05-11 HK HK11104615.4A patent/HK1150628A1/xx unknown
- 2011-12-21 US US13/332,976 patent/US9161810B2/en active Active
-
2015
- 2015-01-23 HK HK15100739.9A patent/HK1200485A1/xx unknown
- 2015-04-03 JP JP2015076575A patent/JP2015131846A/ja active Pending
- 2015-07-30 IL IL240242A patent/IL240242A0/en unknown
- 2015-11-04 US US14/932,200 patent/US20180111982A2/en not_active Abandoned
-
2016
- 2016-05-17 JP JP2016098558A patent/JP6359051B2/ja active Active
- 2016-10-31 IL IL248652A patent/IL248652A0/en active IP Right Grant
-
2017
- 2017-04-26 JP JP2017086871A patent/JP6637465B2/ja active Active
- 2017-09-29 US US15/720,912 patent/US11261241B2/en active Active
-
2019
- 2019-12-20 JP JP2019230026A patent/JP2020050666A/ja active Pending
-
2022
- 2022-03-31 JP JP2022059633A patent/JP2022089873A/ja active Pending
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10226531B2 (en) | 2010-09-27 | 2019-03-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
US9320919B2 (en) | 2010-11-22 | 2016-04-26 | Siwa Corporation | Selective removal of cells having accumulated agents |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US11873345B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Product and method for treating sarcopenia |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010152693A (ru) | Способы, композиции и приборы для облегчения регенерации | |
CA2555955A1 (en) | Pulse manipulation for controlling a phacoemulsification surgical system | |
US20070011940A1 (en) | Intermittent insect trap | |
ES2158962T3 (es) | Cebo liquido para insectos. | |
JP2013236562A (ja) | 害虫防除照明装置 | |
WO2008149286A3 (en) | A lighting system for horticultural applications | |
BR9915306A (pt) | Método e dispositivo para atrair insetos | |
CN204443819U (zh) | 一种蚊虫诱捕器 | |
WO2004042033A3 (en) | Circulating stem cells and uses related thereto | |
JP2015525572A5 (ru) | ||
ES2032356B1 (es) | Cebo envenenado para la erradicacion de insectos nocivos. | |
WO2001075453A3 (en) | Methods involving induced dimerisation by cellular components | |
CN201115387Y (zh) | 一种灭蚊器 | |
CN104521927A (zh) | 新型灭蚊拍 | |
JP4449611B2 (ja) | 天敵昆虫類誘引システム及び同システムの設置方法 | |
BR0015510A (pt) | Método e dispositivo para atrair insetos | |
Ali et al. | A simulation breakdown the blood clot using a free electron laser system | |
CN204499204U (zh) | 一种智能型太阳能粘虫器 | |
MY141549A (en) | Insect trap | |
CN105028363A (zh) | 一种基于太阳能的驱鸟灭虫装置 | |
CN205284703U (zh) | 一种振动式消音灭虫器 | |
CN104756886A (zh) | 组装式社会应激笼 | |
JP5952997B2 (ja) | シロアリの防除方法 | |
PE20020960A1 (es) | Concentracion y lisis de celulas infectadas por adenovirus en una unica operacion unitaria | |
KR101196585B1 (ko) | 해충퇴치 기능을 가지는 전등 |